Morningstar | Ceasing Coverage of Monash IVF
We plan to cease coverage of no-moat Monash IVF in early November 2018. We provide broad coverage of more than 1,500 companies across more than 90 industry groups globally and adjust our coverage as necessary based on client demand and investor interest. Monash is a small, high-risk, no-moat company. The firm’s near-term earnings growth looks to remain muted, with management guiding to a 15% decline in first-half 2019 earnings compared with first-half 2018, given the inclusion of one quarter of activity from a departed key fertility specialist in Australia in the prior period. Nonetheless, we remain positive on Monash’s growth opportunities in Asia given the rising middle class and growing demand for in vitro fertilisation.Healthbridge Enterprises is engaged in the provision of medical services in the area of human reproduction and human pathology.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.